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Background: Haemophilus inﬂuenzae causes community-
acquired respiratory tract and invasive infections in humans.
Resistance to macrolides and ﬂuoroquinolones is emerging in H.
inﬂuenzae limiting its therapeutic options. In the present study we
demonstrated in vitro and in vivo potential of this novel ketolide
against H. inﬂuenzae.
Methods&Materials:MIC of fresh clinical isolates ofH. inﬂuen-
zae (n=145) (- lactamase producer, non-producer strains and
standard ATCC quality control strains) from tertiary care centers in
India was evaluated using microbroth dilution method (CLSI). Bac-
tericidal potential was evaluated using time kill kinetics method
against 3 strains. Immunocompromised mouse and rat pneumonia
model were performed against 2 clinical isolates of H. inﬂuen-
zae. Plasma and ELF concentrations were estimated using standard
HPLC analysis and Microbiological method.
Results: Ketolide A showed MIC range of 0.03 - 4g/ml against
fresh clinical isolates of H. inﬂuenzae. Ketolide A was bactericidal
against 3 different strains of H. inﬂuenzae at 4X MIC concentration
and the results were comparable with telithromycin. Ketolide A
showed>1 log10 reduction in theCFU/lungs compared to2hcontrol
at 100 mg/kg BW PO bid in rat and mouse immunocompromised
pulmonary infection models. The efﬁcacy of ketolide A correlated
with its accumulation in rat lung tissue much above its MIC levels
(1-2g/ml) upto 8h.
Conclusion: Efﬁcacy of ketolideA in rodentH. inﬂuenzaemodels
and high concentration in ELF and lung tissue warrants its further
investigation for the treatment of H. inﬂuenzae infections.
http://dx.doi.org/10.1016/j.ijid.2016.02.321
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Synthesis and antibacterial activity of novel
3’-N-alkyl ketolide and ﬂuoro-ketolide
carbamates against community acquired
respiratory pathogens
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Background:Macrolidesused inclinic areassociatedwithnum-
ber of shortcomings. Our research efforts were directed towards
identiﬁcation of novel macrolides that will address these issues.
Methods & Materials: We report herein, modiﬁcations at 3’-N
and C-2 position of the macrolide ring system. A series of ketolides
and 2-ﬂuoro-ketolides 11, 12-cyclic carbamates in which one of
the methyl of the 3’-N,N-dimethyl group was replaced by the
other alkyl group were synthesized and evaluated against relevant
macrolide-sensitive andmacrolide resistant respiratorypathogens.
Results: Excellent in-vitro activities with MIC range of 0.008-
0.125 against gram positive S.pneumoniae and 0.06 - 16g/ml
against macrolide resistant S.pneumoniae strains were demon-
strated for someof theC2-ﬂuoroketolides. Fewof themalso showed
excellent activity against S aureus and S. pyogenes strains. Modula-
tion of the activity was also observed with modiﬁcation on 3’-N
position.
Conclusion: We have synthesized novel series of ketolide and
C2-ﬂuoroketolide antibiotics that exhibited good in-vitro activity
against the macrolide resistant pathogens including lab generated
telithromycin resistant S.pneumoniae strains. Moreover, the struc-
ture activity relationship study of these compounds led to the
discovery of a novel ﬂuoroketolide lead.
http://dx.doi.org/10.1016/j.ijid.2016.02.322
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Background: The pharmacokinetic compatibility of short-
actingCDRI candidate antimalarial trioxanederivative, 99-411,was
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tested with long-acting prescription antimalarials, lumefantrine
and piperaquine.
Methods & Materials: LC-ESI-MS/MS methods were validated
for simultaneous bioanalysis of lumefantrine and 99-411 and of
piperaquine and 99-411 combinations. The interaction studies
were performed in rats using these validated methods.
Results: The total systemic exposure of 99-411 increased when
administered with either lumefantrine or piperaquine. However,
co-administration of 99-411 signiﬁcantly decreased the systemic
exposure of piperaquine by half-fold while it had no effect on the
kinetics of lumefantrine. 99-411, thus, seemed to be a good alter-
native to artemisinin derivatives for combination treatment with
lumefantrine. To explore the reason for increased plasma levels
of 99-411, an in situ permeability study was performed by co-
perfusing lumefantrine and 99-411. In presence of lumefantrine,
the absorption of 99-411 was signiﬁcantly increased by 1.37 times
than when given alone.
Conclusion: Short-acting CDRI candidate antimalarial trioxane
derivative, 99-411, was found to be pharmacokinetically compati-
ble with long-acting prescription antimalarials, lumefantrine.
http://dx.doi.org/10.1016/j.ijid.2016.02.323
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Designing new antimalarial hits from African
medicinal plants at the University of Buea
(Cameroon); Part I: Isolation, in vitro activity, in
silico “drug-likeness” and Pharmacokinetic
proﬁles
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Background: Drug resistance has drastically exacerbated the
burden of malaria in Africa. It is therefore an urgent need to design
novel therapies both efﬁcacious, safe and affordable especially to
poor people of endemic remote areas. The Malaria Drug discov-
ery programme of the University of Buea (Cameroon) aims to
identify the compounds responsible for the anti-malarial activity
of medicinal plants commonly used in handling malaria symp-
toms by traditional healers of Cameroon. The present paper report
on the potential of selected compounds idenﬁed from Dacryoedes
edulis (Burseraceae), Kigelia africana (Bignoniaceae) and Hypericum
lanceolatum (Hypericaceae), and their suitability as leads for the
treatment of drug resistant malaria.
Methods & Materials: 17 compounds were isolated from
the various extracts of the three plants and tested against both
chloroquine-susceptible (3D&, and D6) and multidrug-resistant
Dd2, W2, K1 and W2mef) strains of Plasmodium falciparum, using
the parasite lactate dehydrogenase method. Cytotoxicity studies
were carried out on LLC-MK2 monkey kidney epithelial cell-line.
In silico analysis was conducted by calculating molecular descrip-
tors using the MOE software running on a Linux workstation. The
“drug-likeness” of the isolated compounds was assessed using Lip-
inski criteria, from computedmolecular properties of the geometry
optimized structures. Computed descriptors often used to pre-
dict absorption, distribution, metabolism, elimination and toxicity
(ADMET) were used to assess the pharmacokinetic proﬁles of the
isolated compounds.
Results: Antiplasmodial activity was demonstrated for the ﬁrst
time in 7 major natural products previously identiﬁed in D. edulis,
H. lanceolatum and Kigelia africana, but not tested against malaria
parasites. The most active compound identiﬁed was termed DES4
from D. edulis. with IC50 of 0.37 and 0.55g/mL, against 3D7 and
Dd2 respectively. In addition, this compound was shown to act
in synergy with quinine, satisﬁed all criteria of “Drug-likeness”
and showed considerable probability of providing an antimalarial
lead. The remaining four compounds also showed antiplasmodial
activity, but were less effective than DES4. None of the tested com-
pounds was cytotoxicity against LLC-MK2 cells, suggesting their
selective activities on malaria parasites.
Conclusion: Based on the high in vitro activity, low toxicity and
predicted “Drug-likeness” DES4 merits further investigation as a
possible drug lead for the treatment of malaria.
http://dx.doi.org/10.1016/j.ijid.2016.02.324
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Distribution of emm types of beta hemolytic
streptococci associated with necrotizing
fascitis: Clinical proﬁle and outcome
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Background: Necrotizing fasciitis (NF) is a rapidly progressive,
potentially life threatening infection with a median mortality rate
of 32% which may reach 100% without prompt treatment. Based
on etiology necrotizing fascitis is classiﬁed into, type I (polymi-
crobial infections), type II (monomicrobial infections, classically
caused by Streptococcus pyogenes), and type III (Clostridial infec-
tions). The present study was undertaken to ﬁnd the prevalence
and emmtypes of beta hemolytic streptococci (BHS) causing necro-
tizing fascitis and to investigate the clinical characteristics and
outcomes associated with it.
Methods & Materials: All BHS isolated from necrotizing fascitis
casesoveraperiodof twoyears (1st October2013 to30th September
2015) in the Department of Microbiology, JIPMER were included in
the study. These isolates were further characterized by bacitracin
sensitivity, PYR test, Lanceﬁeld antigen detection and spy1258 PCR.
PCR ampliﬁcation and sequencing of emmgenes and assignment of
emm types was performed as described by the Center for Disease
Control and Prevention, Atlanta.
Results: Out of a total of 651 cases of NF, 23(3.5%) were asso-
ciated with BHS. Eight (34.7%) were monomicrobial, and 15(65.2%)
were polymicrobial. Inmonomicrobial NF, themajor pathogenwas
GAS. Among BHS isolates 19 were group A streptococci (GAS), 2
each belonged to group F and group C and 1 was group G. All the 19
Mtyped isolates (GAS-17,GCS-2,GGS-1)belonged todifferent emm
types (emm44 (n=3), emm222.2, emm4.5, emm8, emm193, emm63,
emm86.2, emm 80, emm74, emm15.2, emm82.1, emm113, emm110,
emm209, StC28k, StC1741, StG11).
